The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
California's SB 1089, signed into law on September 28, 2026, started as a proposal to require GLP-1 coverage for public employees and was scaled back to a CalRx effort to lower GLP-1 prices. Here's what the law does, why Medi-Cal ended obesity coverage, and what you can do right now if cost is standing between you and treatment.
Since July 1, 2026, the Medicare GLP-1 Bridge has offered eligible Part D enrollees Foundayo, Wegovy, or Zepbound KwikPen for $50 a month. But people with type 2 diabetes, sleep apnea, or fatty liver disease, and anyone already on a Part D covered GLP-1, are excluded. Here's who qualifies, who doesn't, and what to do instead.
Novo Nordisk has filed a lawsuit against Eli Lilly over advertising claims related to their GLP-1 medications. This legal battle between two pharmaceutical giants could affect how patients and pharmacists understand these drugs. Here's what you need to know and why it matters for your treatment decisions.
Hanmi Pharmaceutical is preparing to launch Eppe, a Korean-made GLP-1 weight loss medication that could put real pricing pressure on Wegovy and Mounjaro. Here's what patients currently researching or taking GLP-1 medications should understand about this new competitor and what it might mean for costs.
The European Medicines Agency granted Mounjaro a formal weight management indication, expanding access to tirzepatide for obesity treatment across Europe. If you're considering GLP-1 therapy, here's what this approval means for eligibility, coverage, and your options on both sides of the Atlantic.
Emerging research is exploring whether GLP-1 medications like semaglutide could help treat opioid use disorder, not just obesity. Scientists believe these drugs may reduce cravings by affecting reward pathways in the brain. Here's what the current evidence says and what questions to bring to your doctor.
Novo Nordisk has launched clinical trials testing lower maintenance doses of oral semaglutide (oral Wegovy). This development could expand access and improve tolerability for patients who struggle with injectable GLP-1 medications. Here's what current and prospective patients need to know right now.
Emerging research is revealing important connections between GLP-1 medications and breast cancer, from potential protective effects to questions still being studied. If you are taking or considering semaglutide or tirzepatide, here is what the latest science says and what to discuss with your doctor.